HomeCompareIRBTQ vs JNJ

IRBTQ vs JNJ: Dividend Comparison 2026

IRBTQ yields 3703.70% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IRBTQ wins by $3419432698355.11M in total portfolio value
10 years
IRBTQ
IRBTQ
● Live price
3703.70%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3419432698355.14M
Annual income
$3,246,975,791,785,894,400.00
Full IRBTQ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — IRBTQ vs JNJ

📍 IRBTQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRBTQJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRBTQ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IRBTQ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRBTQ
Annual income on $10K today (after 15% tax)
$314,814.81/yr
After 10yr DRIP, annual income (after tax)
$2,759,929,423,018,010,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, IRBTQ beats the other by $2,759,929,423,018,006,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRBTQ + JNJ for your $10,000?

IRBTQ: 50%JNJ: 50%
100% JNJ50/50100% IRBTQ
Portfolio after 10yr
$1709716349177.59M
Annual income
$1,623,487,895,892,949,500.00/yr
Blended yield
94.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

IRBTQ
Analyst Ratings
8
Buy
14
Hold
2
Sell
Consensus: Hold
Price Target
$65.00
+120270.4% upside vs current
Range: $45.00 — $85.00
Altman Z
-1.9
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRBTQ buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRBTQJNJ
Forward yield3703.70%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3419432698355.14M$30.3K
Annual income after 10y$3,246,975,791,785,894,400.00$4,689.40
Total dividends collected$3407630335185.05M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$65.00$228.73

Year-by-year: IRBTQ vs JNJ ($10,000, DRIP)

YearIRBTQ PortfolioIRBTQ Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$381,070$370,370.37$10,592$272.30+$370.5KIRBTQ
2$13,598,135$13,190,390.11$11,289$357.73+$13.59MIRBTQ
3$454,444,009$439,894,003.67$12,123$472.89+$454.43MIRBTQ
4$14,225,576,546$13,739,321,457.33$13,141$629.86+$14225.56MIRBTQ
5$417,170,412,680$401,949,045,774.95$14,408$846.81+$417170.40MIRBTQ
6$11,462,547,850,090$11,016,175,508,522.75$16,021$1,151.60+$11462547.83MIRBTQ
7$295,153,060,460,047$282,888,134,260,450.30$18,122$1,588.22+$295153060.44MIRBTQ
8$7,123,461,634,615,992$6,807,647,859,923,741.00$20,930$2,228.20+$7123461634.60MIRBTQ
9$161,174,679,036,678,200$153,552,575,087,639,100.00$24,792$3,191.91+$161174679036.65MIRBTQ
10$3,419,432,698,355,140,000$3,246,975,791,785,894,400.00$30,274$4,689.40+$3419432698355.11MIRBTQ

IRBTQ vs JNJ: Complete Analysis 2026

IRBTQStock

iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers Roomba Combo 10 Max robot + AutoWash Dock, a robot vacuum and mop that vacuum and mop multiple floor types while the dock automatically refills and recharges the robot, washes and dries the mopping pad, empties debris, and self-cleans; and Roomba Combo which performs both mopping and vacuuming. It also provides Roomba floor vacuuming robots; accessories and consumables, such as the Clean Base Automatic Dirt Disposal system, replacement dirt disposal bags, mop pads, floor cleaning solution, filters, brushes, and other replacement parts; and service plans for floorcare robots, including an option to cover accidental damage, as well as subscription services. The company sells its products through chain stores and other national retailers, value- added distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts. On December 14, 2025, iRobot Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full IRBTQ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this IRBTQ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRBTQ vs SCHDIRBTQ vs JEPIIRBTQ vs OIRBTQ vs KOIRBTQ vs MAINIRBTQ vs ABBVIRBTQ vs MRKIRBTQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.